These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 21080647)

  • 1. Discovery of 2-(6-{[(6-fluoroquinolin-2-yl)methyl]amino}bicyclo[3.1.0]hex-3-yl)-N-hydroxypyrimidine-5-carboxamide (CHR-3996), a class I selective orally active histone deacetylase inhibitor.
    Moffat D; Patel S; Day F; Belfield A; Donald A; Rowlands M; Wibawa J; Brotherton D; Stimson L; Clark V; Owen J; Bawden L; Box G; Bone E; Mortenson P; Hardcastle A; van Meurs S; Eccles S; Raynaud F; Aherne W
    J Med Chem; 2010 Dec; 53(24):8663-78. PubMed ID: 21080647
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of (2E)-3-{2-butyl-1-[2-(diethylamino)ethyl]-1H-benzimidazol-5-yl}-N-hydroxyacrylamide (SB939), an orally active histone deacetylase inhibitor with a superior preclinical profile.
    Wang H; Yu N; Chen D; Lee KC; Lye PL; Chang JW; Deng W; Ng MC; Lu T; Khoo ML; Poulsen A; Sangthongpitag K; Wu X; Hu C; Goh KC; Wang X; Fang L; Goh KL; Khng HH; Goh SK; Yeo P; Liu X; Bonday Z; Wood JM; Dymock BW; Kantharaj E; Sun ET
    J Med Chem; 2011 Jul; 54(13):4694-720. PubMed ID: 21634430
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimization of potent, selective, and orally bioavailable pyrrolodinopyrimidine-containing inhibitors of heat shock protein 90. Identification of development candidate 2-amino-4-{4-chloro-2-[2-(4-fluoro-1H-pyrazol-1-yl)ethoxy]-6-methylphenyl}-N-(2,2-difluoropropyl)-5,7-dihydro-6H-pyrrolo[3,4-d]pyrimidine-6-carboxamide.
    Zehnder L; Bennett M; Meng J; Huang B; Ninkovic S; Wang F; Braganza J; Tatlock J; Jewell T; Zhou JZ; Burke B; Wang J; Maegley K; Mehta PP; Yin MJ; Gajiwala KS; Hickey MJ; Yamazaki S; Smith E; Kang P; Sistla A; Dovalsantos E; Gehring MR; Kania R; Wythes M; Kung PP
    J Med Chem; 2011 May; 54(9):3368-85. PubMed ID: 21438541
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic optimization of class-selective histone deacetylase inhibitors and identification of associated candidate predictive biomarkers of hepatocellular carcinoma tumor response.
    Wong JC; Tang G; Wu X; Liang C; Zhang Z; Guo L; Peng Z; Zhang W; Lin X; Wang Z; Mei J; Chen J; Pan S; Zhang N; Liu Y; Zhou M; Feng L; Zhao W; Li S; Zhang C; Zhang M; Rong Y; Jin TG; Zhang X; Ren S; Ji Y; Zhao R; She J; Ren Y; Xu C; Chen D; Cai J; Shan S; Pan D; Ning Z; Lu X; Chen T; He Y; Chen L
    J Med Chem; 2012 Oct; 55(20):8903-25. PubMed ID: 23061376
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of a potent, selective, and orally bioavailable pyridinyl-pyrimidine phthalazine aurora kinase inhibitor.
    Cee VJ; Schenkel LB; Hodous BL; Deak HL; Nguyen HN; Olivieri PR; Romero K; Bak A; Be X; Bellon S; Bush TL; Cheng AC; Chung G; Coats S; Eden PM; Hanestad K; Gallant PL; Gu Y; Huang X; Kendall RL; Lin MH; Morrison MJ; Patel VF; Radinsky R; Rose PE; Ross S; Sun JR; Tang J; Zhao H; Payton M; Geuns-Meyer SD
    J Med Chem; 2010 Sep; 53(17):6368-77. PubMed ID: 20684549
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of a series of substituted 2-piperazinyl-5-pyrimidylhydroxamic acids as potent histone deacetylase inhibitors.
    Angibaud P; Van Emelen K; Decrane L; van Brandt S; Ten Holte P; Pilatte I; Roux B; Poncelet V; Speybrouck D; Queguiner L; Gaurrand S; Mariën A; Floren W; Janssen L; Verdonck M; van Dun J; van Gompel J; Gilissen R; Mackie C; Du Jardin M; Peeters J; Noppe M; Van Hijfte L; Freyne E; Page M; Janicot M; Arts J
    Bioorg Med Chem Lett; 2010 Jan; 20(1):294-8. PubMed ID: 19906529
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potent, selective, and orally bioavailable inhibitors of mammalian target of rapamycin (mTOR) kinase based on a quaternary substituted dihydrofuropyrimidine.
    Cohen F; Bergeron P; Blackwood E; Bowman KK; Chen H; Dipasquale AG; Epler JA; Koehler MF; Lau K; Lewis C; Liu L; Ly CQ; Malek S; Nonomiya J; Ortwine DF; Pei Z; Robarge KD; Sideris S; Trinh L; Truong T; Wu J; Zhao X; Lyssikatos JP
    J Med Chem; 2011 May; 54(9):3426-35. PubMed ID: 21495671
    [TBL] [Abstract][Full Text] [Related]  

  • 8. N-hydroxy-3-phenyl-2-propenamides as novel inhibitors of human histone deacetylase with in vivo antitumor activity: discovery of (2E)-N-hydroxy-3-[4-[[(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2-propenamide (NVP-LAQ824).
    Remiszewski SW; Sambucetti LC; Bair KW; Bontempo J; Cesarz D; Chandramouli N; Chen R; Cheung M; Cornell-Kennon S; Dean K; Diamantidis G; France D; Green MA; Howell KL; Kashi R; Kwon P; Lassota P; Martin MS; Mou Y; Perez LB; Sharma S; Smith T; Sorensen E; Taplin F; Trogani N; Versace R; Walker H; Weltchek-Engler S; Wood A; Wu A; Atadja P
    J Med Chem; 2003 Oct; 46(21):4609-24. PubMed ID: 14521422
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis and biological characterization of amidopropenyl hydroxamates as HDAC inhibitors.
    Thaler F; Varasi M; Colombo A; Boggio R; Munari D; Regalia N; Rozio MG; Reali V; Resconi AE; Mai A; Gagliardi S; Dondio G; Minucci S; Mercurio C
    ChemMedChem; 2010 Aug; 5(8):1359-72. PubMed ID: 20572281
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of N,1,4,4-tetramethyl-8-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide (PHA-848125), a potent, orally available cyclin dependent kinase inhibitor.
    Brasca MG; Amboldi N; Ballinari D; Cameron A; Casale E; Cervi G; Colombo M; Colotta F; Croci V; D'Alessio R; Fiorentini F; Isacchi A; Mercurio C; Moretti W; Panzeri A; Pastori W; Pevarello P; Quartieri F; Roletto F; Traquandi G; Vianello P; Vulpetti A; Ciomei M
    J Med Chem; 2009 Aug; 52(16):5152-63. PubMed ID: 19603809
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and antitumor effect in vitro and in vivo of substituted 1,3-dihydroindole-2-ones.
    Christensen MK; Erichsen KD; Trojel-Hansen C; Tjørnelund J; Nielsen SJ; Frydenvang K; Johansen TN; Nielsen B; Sehested M; Jensen PB; Ikaunieks M; Zaichenko A; Loza E; Kalvinsh I; Björkling F
    J Med Chem; 2010 Oct; 53(19):7140-5. PubMed ID: 20845961
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SAR and biological evaluation of analogues of a small molecule histone deacetylase inhibitor N-(2-aminophenyl)-4-((4-(pyridin-3-yl)pyrimidin-2-ylamino)methyl)benzamide (MGCD0103).
    Raeppel S; Zhou N; Gaudette F; Leit S; Paquin I; Larouche G; Moradei O; Fréchette S; Isakovic L; Delorme D; Fournel M; Kalita A; Lu A; Trachy-Bourget MC; Yan PT; Liu J; Rahil J; Wang J; Besterman JM; Murakami K; Li Z; Vaisburg A
    Bioorg Med Chem Lett; 2009 Feb; 19(3):644-9. PubMed ID: 19114304
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design, synthesis and bioevalution of novel benzamides derivatives as HDAC inhibitors.
    Li Y; Zhou Y; Qian P; Wang Y; Jiang F; Yao Z; Hu W; Zhao Y; Li S
    Bioorg Med Chem Lett; 2013 Jan; 23(1):179-82. PubMed ID: 23206867
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of a potent class I selective ketone histone deacetylase inhibitor with antitumor activity in vivo and optimized pharmacokinetic properties.
    Kinzel O; Llauger-Bufi L; Pescatore G; Rowley M; Schultz-Fademrecht C; Monteagudo E; Fonsi M; Gonzalez Paz O; Fiore F; Steinkühler C; Jones P
    J Med Chem; 2009 Jun; 52(11):3453-6. PubMed ID: 19441846
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, synthesis and anticancer activity of piperazine hydroxamates and their histone deacetylase (HDAC) inhibitory activity.
    Chetan B; Bunha M; Jagrat M; Sinha BN; Saiko P; Graser G; Szekeres T; Raman G; Rajendran P; Moorthy D; Basu A; Jayaprakash V
    Bioorg Med Chem Lett; 2010 Jul; 20(13):3906-10. PubMed ID: 20605448
    [TBL] [Abstract][Full Text] [Related]  

  • 16. N-Hydroxy-1,2-disubstituted-1H-benzimidazol-5-yl acrylamides as novel histone deacetylase inhibitors: design, synthesis, SAR studies, and in vivo antitumor activity.
    Wang H; Yu N; Song H; Chen D; Zou Y; Deng W; Lye PL; Chang J; Ng M; Sun ET; Sangthongpitag K; Wang X; Wu X; Khng HH; Fang L; Goh SK; Ong WC; Bonday Z; Stünkel W; Poulsen A; Entzeroth M
    Bioorg Med Chem Lett; 2009 Mar; 19(5):1403-8. PubMed ID: 19181524
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, synthesis, structure--selectivity relationship, and effect on human cancer cells of a novel series of histone deacetylase 6-selective inhibitors.
    Itoh Y; Suzuki T; Kouketsu A; Suzuki N; Maeda S; Yoshida M; Nakagawa H; Miyata N
    J Med Chem; 2007 Nov; 50(22):5425-38. PubMed ID: 17929798
    [TBL] [Abstract][Full Text] [Related]  

  • 18. YM753, a novel histone deacetylase inhibitor, exhibits antitumor activity with selective, sustained accumulation of acetylated histones in tumors in the WiDr xenograft model.
    Shindoh N; Mori M; Terada Y; Oda K; Amino N; Kita A; Taniguchi M; Sohda KY; Nagai K; Sowa Y; Masuoka Y; Orita M; Sasamata M; Matsushime H; Furuichi K; Sakai T
    Int J Oncol; 2008 Mar; 32(3):545-55. PubMed ID: 18292931
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New aryldithiolethione derivatives as potent histone deacetylase inhibitors.
    Tazzari V; Cappelletti G; Casagrande M; Perrino E; Renzi L; Del Soldato P; Sparatore A
    Bioorg Med Chem; 2010 Jun; 18(12):4187-94. PubMed ID: 20576572
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis and biological evaluation of N-hydroxyphenylacrylamides and N-hydroxypyridin-2-ylacrylamides as novel histone deacetylase inhibitors.
    Thaler F; Colombo A; Mai A; Amici R; Bigogno C; Boggio R; Cappa A; Carrara S; Cataudella T; Fusar F; Gianti E; di Ventimiglia SJ; Moroni M; Munari D; Pain G; Regalia N; Sartori L; Vultaggio S; Dondio G; Gagliardi S; Minucci S; Mercurio C; Varasi M
    J Med Chem; 2010 Jan; 53(2):822-39. PubMed ID: 20017493
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.